Summary
Over 250 branded drugs in the U.S. will see price increases starting Jan. 1, 2025, with most hikes below 10% and a median increase of 4.5%.
Key companies like Pfizer, Bristol Myers Squibb, and Sanofi are raising prices on treatments for COVID-19, cancer, and vaccines, citing R&D costs and inflation.
Some prices, such as Merck’s diabetes drugs, will be reduced.
Critics highlight that U.S. drug prices remain the highest globally, while manufacturers face pressure to moderate year-over-year price hikes.
Well, the argument is that they need to cover new R&D costs
Know what industry has higher R&D costs than pharmaceuticals? Chips.
And my computers aren’t going up that much